Souza Reynaldo José Sant'Anna Pereira de, Mattedi Adriana P, Corrêa Marcelo P, Rezende Marcelo L, Ferreira Ana Cláudia Andrade
Hospital do Câncer de Franca, SP, Brasil.
An Bras Dermatol. 2011 Jul-Aug;86(4):657-62. doi: 10.1590/s0365-05962011000400005.
The most common form of cancer in Brazil is non-melanoma skin cancer, which affects approximately 0.06% of the population. There are no public policies for its prevention and the economic impact of its diagnosis has yet to be established.
To estimate the costs of the diagnosis and treatment of non-melanoma skin cancer in the state of São Paulo between 2000 and 2007 and to compare them with the costs associated with skin melanoma in the same period.
The Clinical Practice Guidelines in Oncology (National Comprehensive Cancer Network) was used as a procedure model, adapted to the procedures at the SOBECCan Foundation at the Ribeirão Preto Cancer Hospital in São Paulo. The estimated costs were based on the costs of medical treatment in the public and private sectors in 2007.
The mean annual costs of each individual treatment of non-melanoma skin cancer were much lower than those estimated for the treatment of skin melanoma. Nevertheless, when the total costs of the treatment of non-melanoma skin cancer were taken into consideration, it was found that the total cost of the 42,184 cases of this type of cancer in São Paulo within the study period was 14% higher than the costs of the 2,740 cases of skin melanoma registered in the same period within the Brazilian National Health Service (SUS). However, in the private sector, the total cost was approximately 34% less for the treatment of non-melanoma skin cancer compared to melanoma.
The high number of cases of non-melanoma skin cancer in Brazil, with 114,000 new cases predicted for 2010, 95% of which are diagnosed at early stages, represents a financial burden to the public and private healthcare systems of around R$37 million and R$26 million annually, respectively.
巴西最常见的癌症类型是非黑色素瘤皮肤癌，约占总人口的0.06%。目前尚无针对其预防的公共政策，其诊断的经济影响也尚未确定。
估算2000年至2007年圣保罗州非黑色素瘤皮肤癌的诊断和治疗费用，并与同期皮肤黑色素瘤的相关费用进行比较。
采用肿瘤临床实践指南（美国国立综合癌症网络）作为程序模型，并根据圣保罗里贝朗普雷图癌症医院SOBECCan基金会的程序进行调整。估算费用基于2007年公共和私营部门的医疗费用。
非黑色素瘤皮肤癌每次个体治疗的年均费用远低于皮肤黑色素瘤治疗的估算费用。然而，考虑到非黑色素瘤皮肤癌的治疗总费用时，发现研究期间圣保罗州42,184例此类癌症的总费用比巴西国家卫生服务体系（SUS）同期登记的2,740例皮肤黑色素瘤的费用高14%。然而，在私营部门，非黑色素瘤皮肤癌治疗的总费用比黑色素瘤低约34%。
巴西非黑色素瘤皮肤癌病例数量众多，预计2010年有114,000例新病例，其中95%在早期被诊断，这分别给公共和私营医疗系统带来了每年约3700万雷亚尔和2600万雷亚尔的经济负担。
